Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for OATP Inhibition

[1]  H. Kusuhara,et al.  Effect of Rifampicin on the Plasma Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted Chimeric Mice With or Without Bile Flow Diversion. , 2019, Journal of pharmaceutical sciences.

[2]  Kenta Yoshida,et al.  GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study , 2019, Drug Metabolism and Disposition.

[3]  P. Marathe,et al.  Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate. , 2019, Molecular pharmaceutics.

[4]  W. Humphreys,et al.  Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug–Drug Interaction and Associated Biomarker Levels in Healthy Volunteers , 2019, Clinical and translational science.

[5]  H. Yamazaki,et al.  Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes , 2019, Biopharmaceutics & drug disposition.

[6]  R. Levy,et al.  Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017 , 2018, Drug Metabolism and Disposition.

[7]  J. Ware,et al.  Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects , 2018, Journal of clinical pharmacology.

[8]  Yuichi Sugiyama,et al.  Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.

[9]  A. D. Rodrigues,et al.  PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3 , 2018, CPT: pharmacometrics & systems pharmacology.

[10]  Jiachang Gong,et al.  Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition , 2018, Drug Metabolism and Disposition.

[11]  R. Sane,et al.  Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics , 2018, CPT: pharmacometrics & systems pharmacology.

[12]  A. D. Rodrigues,et al.  Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance , 2018, Drug Metabolism and Disposition.

[13]  A. D. Rodrigues,et al.  Simultaneous Assessment of Transporter-Mediated Drug–Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey , 2018, Drug Metabolism and Disposition.

[14]  A. D. Rodrigues,et al.  In Vitro–In Vivo Extrapolation of OATP1B-Mediated Drug–Drug Interactions in Cynomolgus Monkey , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[15]  Hong Shen.  A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers. , 2018, Bioanalysis.

[16]  K. Maeda,et al.  Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers , 2018, Pharmaceutical Research.

[17]  M. Monshouwer,et al.  Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions , 2018, Clinical Pharmacokinetics.

[18]  F. Müller,et al.  Biomarkers for In Vivo Assessment of Transporter Function , 2018, Pharmacological Reviews.

[19]  H. Kusuhara,et al.  Endogenous Probes for Drug Transporters: Balancing Vision With Reality , 2018, Clinical pharmacology and therapeutics.

[20]  Kayode Ogungbenro,et al.  Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation , 2018, Clinical pharmacology and therapeutics.

[21]  P. Marathe,et al.  Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes. , 2017, Current drug metabolism.

[22]  X. Chu,et al.  Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. , 2017, Journal of pharmaceutical sciences.

[23]  W. Humphreys,et al.  Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects , 2017, Drug Metabolism and Disposition.

[24]  A. D. Rodrigues,et al.  Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides , 2017, Drug Metabolism and Disposition.

[25]  H. Yamazaki,et al.  Pre‐incubation with cyclosporine A potentiates its inhibitory effects on pitavastatin uptake mediated by recombinantly expressed cynomolgus monkey hepatic organic anion transporting polypeptide , 2016, Biopharmaceutics & drug disposition.

[26]  W. Humphreys,et al.  Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[27]  W. Humphreys,et al.  Tissue distribution and tumor uptake of folate receptor–targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration , 2016, Acta pharmaceutica Sinica. B.

[28]  D. Bednarczyk,et al.  Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III , 2016, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  W. Humphreys,et al.  Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[30]  A. D. Rodrigues,et al.  Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation , 2015, Drug Metabolism and Disposition.

[31]  X. Chu,et al.  Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans , 2015, Drug Metabolism and Disposition.

[32]  A. D. Rodrigues,et al.  Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[33]  X. Chu,et al.  Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics , 2015, Drug Metabolism and Disposition.

[34]  H. Yamazaki,et al.  Pitavastatin as an In Vivo Probe for Studying Hepatic Organic Anion Transporting Polypeptide-Mediated Drug–Drug Interactions in Cynomolgus Monkeys , 2013, Drug Metabolism and Disposition.

[35]  Y. Sugiyama,et al.  Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG‐CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism , 2013, Clinical pharmacology and therapeutics.

[36]  A. D. Rodrigues,et al.  Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[37]  P. Mustajoki,et al.  Hereditary hepatic porphyrias in Finland. , 2009, Acta medica Scandinavica.

[38]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[39]  M. Fromm,et al.  Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[40]  R. Kim,et al.  Pharmacogenomics of the OATP and OAT families. , 2004, Pharmacogenomics.

[41]  J. Ringers,et al.  Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting , 2001, Transplant international : official journal of the European Society for Organ Transplantation.

[42]  Joachim Grevel,et al.  Improved Dose Linearity of Cyclosporine Pharmacokinetics from a Microemulsion Formulation , 1994, Pharmaceutical Research.

[43]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[44]  B. Kasiske,et al.  Long‐term cyclosporine pharmacokinetic changes in renal transplant recipients: Effects of binding and metabolism , 1989, Clinical pharmacology and therapeutics.

[45]  P. Gaffney,et al.  The relationship between plasma vasopressin and changes in coagulation and fibrinolysis during hip surgery. , 1988, Thrombosis research.

[46]  T. Trenti,et al.  Coproporphyrin excretion in healthy newborn babies. , 1984, Journal of pediatric gastroenterology and nutrition.

[47]  M. Kohakura,et al.  Urinary Coproporphyrin isomers in Rotor's syndrome: A study in eight families , 1981, Hepatology.

[48]  A. Wolkoff,et al.  Rotor's syndrome. A distinct inheritable pathophysiologic entity. , 1976, The American journal of medicine.

[49]  N. Kaplowitz,et al.  Coproporphyrin I and 3 excretion in bile and urine. , 1972, The Journal of clinical investigation.

[50]  C. J. Watson,et al.  An analysis of the porphyrins of normal and cirrhotic human liver and normal bile. , 1969, Clinica chimica acta; international journal of clinical chemistry.

[51]  A. Eisalo,et al.  Urinary Excretion of Porphyrin Precursors and Coproporphyrin in Healthy Females on Oral Contraceptives , 1966, British medical journal.

[52]  C. Beglinger,et al.  The absorption site of cyclosporin in the human gastrointestinal tract. , 1992, British journal of clinical pharmacology.

[53]  M. Kekki,et al.  Multicompartment analysis of 14C-labelled coproporphyrin and uroporphyrin kinetics in human beings. , 1976, Annals of clinical research.

[54]  C. Rimington,et al.  Abnormal excretion of the isomers of urinary coproporphyrin by patients with Dubin-Johnson syndrome in Israel. , 1971, Clinical science.